Results 71 to 80 of about 11,219 (248)

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Successful low-dose azathioprine for myasthenia gravis despite hepatopathy from primary sclerosing cholangitis: a case report

Journal of Medical Case Reports, 2010
Introduction Although myasthenia gravis is frequently associated with other disorders, it has not been reported together with primary sclerosing cholangitis, complicating the administration of liver-toxic immunosuppressive therapy. Case presentation A 73-
Höflich Sonja, Finsterer Josef
doaj   +1 more source

Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG‐MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Physical activity and sleep influence fatigue in myasthenia gravis (MG), and digital health technologies (DHT) enable objective monitoring of these behaviors in daily life. Using this approach, we evaluated whether a lifestyle intervention targeting physical activity or sleep hygiene could reduce fatigue in MG.
Maja Norling, Niclas Eriksson, Elisabet Westerberg, Ingela Nygren, Klara Norman, Julia Hedberg, Sui H. Wong, Susanna Jernelöv, Pernilla Åsenlöf, Anna Rostedt Punga   +9 more
wiley   +1 more source

Оцінка тривожності у хворих на міастенію [PDF]

, 2018
У статті представлено результати дослідження тривожності у хворих на міастенію залежно від імунологічного типу, тривалості та клінічної форми захворювання. Мета роботи — дослідити рівень тривожності у дорослих, хворих на міастенію. Матеріал і методи.
Кальбус, О.І.
core  

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Annals of Clinical and Translational Neurology, EarlyView.
Francesco Saccà, Ryan Pelto
wiley   +1 more source

Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six‐week cyclic regimen may be associated with a “wearing‐off” effect and disease fluctuations. We evaluated the non‐cyclic administration
Marc Abi Aoun, Diane Beauvais, Marlène Barnay, Marie‐Hélène Violleau, Stéphane Mathis, Fanny Duval, Guilhem Sole   +6 more
wiley   +1 more source

Epilepsy and Myasthenia Gravis: A Case Series

Brain Sciences
The association between epilepsy and myasthenia gravis has rarely been reported, and when it has been reported, it has only been in a small case series.
Iñigo Oyarzun, Guillermo Hernández, Jacint Sala-Padró, Francisco Morandeira, Carlos Casasnovas, Mercè Falip   +5 more
doaj   +1 more source

Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]

, 2018
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core   +1 more source

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, EarlyView.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

Clinical reasoning in feline non‐ambulatory tetraparesis or tetraplegia: Which combination of clinical information is useful?

Veterinary Record, EarlyView.
Abstract Background Non‐ambulatory tetraparesis or tetraplegia in cats may constitute a diagnostic challenge for general practitioners. Therefore, this study aimed to evaluate if clinical variables from signalment, history, clinical examination and basic ancillary tests are associated with underlying diagnoses in cats with non‐ambulatory tetraparesis ...
Guido Bertoldi, Steven De Decker
wiley   +1 more source